Podchaser Logo
Home
Long-awaited ISCHEMIA results to change practice, DAPA-HF elevates dapagliflozin for HFrEF

Long-awaited ISCHEMIA results to change practice, DAPA-HF elevates dapagliflozin for HFrEF

Released Friday, 22nd November 2019
Good episode? Give it some love!
Long-awaited ISCHEMIA results to change practice, DAPA-HF elevates dapagliflozin for HFrEF

Long-awaited ISCHEMIA results to change practice, DAPA-HF elevates dapagliflozin for HFrEF

Long-awaited ISCHEMIA results to change practice, DAPA-HF elevates dapagliflozin for HFrEF

Long-awaited ISCHEMIA results to change practice, DAPA-HF elevates dapagliflozin for HFrEF

Friday, 22nd November 2019
Good episode? Give it some love!
Rate Episode

ISCHEMIA trial hailed as practice changing

The largest-ever RCT of initial invasive versus conservative management of stable ischemic heart disease makes waves.

*  *  *  

Help us make this podcast better! Please take our short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019

*  *  *  

DAPA-HF: Dapagliflozin’s HFrEF efficacy confirmed in nondiabetics

Further analyses from the DAPA-HF trial showed dapagliflozin cut death and heart failure events in HFrEF patients with no diabetes.

The TWILIGHT of aspirin post-PCI for ACS?

Patients do better post-PCI for non-ST-elevation ACS with ticagrelor monotherapy

Weaknesses exposed in valsartan recall

ED visits for hypertension in month after the 2018 recall spiked 55%

*  *  *  

For more MDedge Podcasts, go to mdedge.com/podcasts

Email the show: podcasts@mdedge.com

Interact with us on Twitter: @MDedgeTweets

Show More
Rate

Join Podchaser to...

  • Rate podcasts and episodes
  • Follow podcasts and creators
  • Create podcast and episode lists
  • & much more

Episode Tags

Do you host or manage this podcast?
Claim and edit this page to your liking.
,

Unlock more with Podchaser Pro

  • Audience Insights
  • Contact Information
  • Demographics
  • Charts
  • Sponsor History
  • and More!
Pro Features